Optimizing Early-Phase CRO Selection: A Due Diligence Framework for Biotech Founders

Most first-in-human Phase I trials begin with single ascending dose cohorts of six to eight subjects, so a CRO without dedicated PK/PD staffing or clear governance can derail your schedule before the first dose. The right early-phase CRO is not the cheapest or largest; it is the one with proven first-in-human experience, transparent oversight, and a team you can reach when a safety signal breaks at 9 p.m. Select for operational and scientific fit, then verify with references and a protocol walkthrough.

Key takeaways

• Phase I and II CRO selection hinges on first-in-human capability, not just therapeutic-area size or global footprint.
• Due diligence should cover scientific fit, PK/PD operations, governance, budget transparency, and the assigned study team.
• Hidden costs usually live in amendment fees, pass-through charges, and poorly defined site initiation or close-out tasks.
• Governance means defined escalation paths, sponsor data access, and a monitoring plan matched to trial risk.
• Treat the CRO as a partner from first dose through Phase II, but re-evaluate before scaling to larger populations.

Why is early-phase CRO selection different from Phase III?

Phase I and II trials are small, adaptive, and safety-led, whereas Phase III is built for recruitment volume and statistical power. A Phase I CRO must manage first-in-human dosing, intensive PK sampling, and rapid protocol amendments with a handful of sites; a Phase III CRO is optimized for enrolling hundreds of patients across many countries. Choosing a Phase III-grade CRO for early work often means paying for infrastructure you do not need while missing the scientific flexibility you do.

In early-phase work, the protocol is a living document. Dose escalation decisions depend on safety data arriving in near real time, and the CRO’s medical monitor and PK scientist need to be embedded in those decisions, not just receiving reports. A large CRO built for Phase III may assign a junior study team to your first-in-human study and rotate staff as soon as a larger project comes in. That turnover is manageable when you are enrolling 600 patients across fifty sites; it is dangerous when you are dosing the first eight subjects in a first-in-human cohort.

Public guidance on choosing a Phase 1 CRO emphasizes therapeutic-area experience and operational transparency as core criteria (Clinical Leader). My rule of thumb: if the CRO’s proposal reads like it was written for a Phase III cardiovascular outcomes trial, it is not the right fit for your first-in-human study.

How do I choose a CRO for a Phase 1 trial?

Start with the protocol, not the vendor list. Define your dose-escalation design, PK/PD requirements, site geography, and safety reporting needs, then issue a focused RFP and score candidates on first-in-human experience, assigned-team quality, site access, quality systems, and budget transparency before checking references and running a protocol walkthrough.

I recommend a shortlist of three to five CROs. Ask each for a redacted protocol from a comparable first-in-human study they ran, and ask to speak with the study manager who actually ran it—not the business development director. Pay attention to whether they ask questions about your molecule’s mechanism, your anticipated safety signals, and your IND-enabling package. A CRO that accepts your RFP without probing the science is a CRO that will execute blindly.

This is also the stage to confirm geographic fit. If your Phase I trial will enroll patients with advanced oncology, you need site access to investigators who treat that population; if it is a healthy-volunteer SAD/MAD study, you need a dedicated clinical pharmacology unit. Do not let a CRO’s broad country list substitute for proof they can access the specific sites you need.

What are the key due diligence pillars for early-stage biotech?

Five pillars should govern every early-phase CRO evaluation: scientific and therapeutic fit, PK/PD capability, governance and oversight, financial transparency, and assigned-team continuity. Score each pillar separately rather than averaging them into a single impression; a weak PK/PD pillar cannot be offset by a strong sales team.

If a CRO cannot produce a named study manager or a CV for the medical monitor who will cover your study, treat that as a due diligence failure, not a minor omission. I also check whether the CRO has run studies under the current regulatory environment—the 2026 FDA and ICH updates changed several reporting expectations that a CRO’s SOPs should already reflect.

How should I evaluate a CRO's PK/PD capabilities?

For early-phase trials, verify that the CRO operates or has a contracted bioanalytical laboratory with validated methods, defined PK sampling windows, and a PK scientist who can interpret data in real time. PK/PD is not a back-office function in first-in-human work; it is the primary readout that drives dose escalation and go/no-go decisions.

Ask to see the bioanalytical method validation report and the standard operating procedure for sample handling, stability, and storage. If samples must be shipped to a third-party lab, confirm the chain-of-custody process and the expected turnaround time. In a single ascending dose study, you may need preliminary PK within 24 to 48 hours to decide whether to proceed to the next dose level. A CRO that quotes a two-week bioanalytical turnaround is not operationally aligned with first-in-human decision-making.

Also ask about pharmacodynamic biomarkers. If your mechanism depends on target engagement, the CRO should be able to describe how they will collect, process, and assay PD samples alongside PK. Cromos Pharma’s guidance on Phase 1 and Phase 2 CRO selection similarly treats laboratory and scientific capability as a threshold requirement rather than a nice-to-have.

What does a CRO governance model look like in clinical trials?

A governance model should define who owns decisions, how safety information flows, and what oversight the sponsor retains. For early-phase trials, I look for a named medical monitor, a risk-based monitoring plan, a trial master file accessible to the sponsor, and a written escalation path for adverse events and protocol deviations.

Governance breaks down most often in the gap between the CRO’s project manager and the sponsor’s clinical lead. If the only communication channel is a monthly status call, you will not learn about a serious adverse event until it is too late to adjust dosing. I expect weekly oversight meetings during active dosing, immediate SAE notification within the timeframe required by regulation, and shared access to source data or at least timely data extracts.

Risk-based monitoring is the appropriate default for early-phase work, but it must be risk-based by design, not by neglect. Risk-based monitoring in 2026 describes how monitoring intensity should match protocol risk, which is exactly the lens to apply when reviewing a CRO’s monitoring plan. Ask for their monitoring plan as a standalone document and check whether it specifies central monitoring, site initiation visits, and for-cause triggers.

How do I uncover hidden costs in a CRO budget?

Request a fully line-itemized budget rather than a bundled fee, and model the cost per patient, per site, and per amendment. Hidden costs in early-phase CRO contracts typically appear as pass-through charges, amendment fees, site initiation and close-out markups, and undefined CRA hours.

I have seen budgets where the per-patient rate looked competitive until the line items for courier services, central lab shipping, IRB fees, and travel were added back in. Amendment fees are another common trap: early-phase protocols change frequently, and some CROs charge a flat fee per amendment regardless of scope. Ask for the amendment fee schedule, the hourly rate for out-of-scope work, and whether site fees are passed through at cost or with a markup.

Payment milestones should align with deliverables, not calendar dates. I prefer payments tied to site initiation, first patient dosed, database lock, and final report acceptance. This keeps the CRO’s incentives aligned with trial progress. For more on controlling these variables, see Optimizing Clinical Trial Budgets in 2026 and The True Cost of Protocol Amendments.

Who will actually run my Phase I study?

The people named in the proposal should be the people who do the work. Require CVs for the principal investigator, study manager, CRA, PK scientist, and medical monitor, and insist on a key-person clause that requires your approval before any of them are replaced.

In early-phase trials, the study manager often functions as the de facto project lead, coordinating between the clinical site, the bioanalytical lab, and the sponsor. The PK scientist interprets concentration-time data to support dose escalation, and the medical monitor makes the safety calls. If any of these roles is filled by someone who has never worked on a first-in-human study, the learning curve comes out of your timeline and your budget.

Ask about backups and turnover. What happens if the study manager leaves mid-study? How quickly can a replacement get up to speed on your protocol? A CRO with a deep bench and documented onboarding for study personnel is safer than a CRO that depends on a single star performer.

What are the red flags in a CRO proposal?

Watch for vague staffing plans, missing first-in-human references, unwillingness to share SOPs or quality documentation, bundled pricing without line items, and timelines that promise first-patient dosed faster than the site network can realistically support.

Specific red flags I have learned to treat as disqualifying:

• The proposal lists therapeutic-area experience but cannot name a single completed first-in-human study in a comparable modality.
• The CRO declines to provide the CV of the proposed medical monitor or study manager.
• The budget is a single flat fee with no breakdown of pass-throughs, site fees, or amendment costs.
• The monitoring plan consists of “standard monitoring” with no risk assessment or sponsor oversight provisions.
• The promised timeline compresses site selection, IRB approval, and first-patient dosed into an unrealistic window, suggesting they have not vetted site feasibility.

One more subtle warning: if the CRO’s sales team is doing all the talking and the operational team never joins the due diligence calls, assume the operational team was not involved in building the proposal. That disconnect usually surfaces after the contract is signed.

Should I keep the same CRO from Phase I into Phase II?

There is no default answer. Continuity offers protocol familiarity and faster startup, but Phase II brings different demands—larger patient populations, more sites, and often a different therapeutic emphasis. Re-evaluate the CRO against Phase II requirements before renewing, and do not let sunk cost lock you into a partner that cannot scale.

If the CRO performed well in Phase I, the strongest argument for staying is institutional memory: they know your molecule, your safety profile, and your preferred reporting cadence. The risk is that a CRO optimized for a six-site first-in-human study lacks the site-management infrastructure, data management bandwidth, or therapeutic bench strength for a multi-site Phase II.

I treat the end of Phase I as a natural decision gate. Score the incumbent against the same five pillars used in the original selection, and invite one or two new CROs to bid on the Phase II scope. If the incumbent wins a fair competition, you have validated the partnership. If they do not, switching now is cheaper than switching after the first patient is dosed in Phase II.

How do I manage a CRO relationship during early clinical development?

Manage the CRO with a fixed meeting cadence, a shared issue log, and joint ownership of protocol deviations and site selection. Early-phase trials move fast, so operational issues should be surfaced weekly, not discovered at the end-of-phase meeting.

Set up a weekly oversight call during active dosing with a standing agenda: enrollment, safety, PK data availability, site performance, and open issues. Use a shared issue log with owners and due dates, and review protocol deviations as they occur rather than in aggregate at study end. For site selection, involve the CRO early but retain sponsor approval over final site choices; data-driven site selection works best when sponsor and CRO align on feasibility criteria before sites are activated.

Also schedule an end-of-Phase-I meeting to review what worked and what did not before any Phase II planning begins. That conversation is where you decide whether to renew, renegotiate, or re-compete.

If you want a structured way to pressure-test a CRO before signing, Clinical Trial OS runs a six-pillar feasibility assessment and issues a go/no-go verdict with every figure cited to its public source. Learn more at Clinical Trial OS.

FAQ

How do I choose a CRO for a phase 1 trial?

Define your dose-escalation design, PK/PD needs, and site geography first, then score CROs on first-in-human experience, assigned-team quality, governance, and budget transparency before checking references.

What are phase 1 CRO selection criteria?

Key criteria include scientific and therapeutic fit, PK/PD laboratory capability, governance and oversight structure, financial transparency, and continuity of the assigned study team.

What does CRO governance look like in early clinical trials?

It should include a named medical monitor, a risk-based monitoring plan, sponsor access to the trial master file, weekly oversight during dosing, and a written escalation path for adverse events.

Is the cheapest CRO the most cost-effective option for a biotech?

Not necessarily. A low headline price can conceal pass-through costs, amendment fees, and staffing gaps that cost more over the life of a first-in-human study than a higher-priced, transparent alternative.

Should I switch CROs between Phase I and Phase II?

Re-evaluate at the end of Phase I. Continuity has value, but Phase II often demands greater scale and site-management capacity, so the incumbent should compete fairly against alternatives before being renewed.